{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:49:24Z","timestamp":1791532164802,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1139466"],"award-info":[{"award-number":["1139466"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1135107"],"award-info":[{"award-number":["1135107"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2041063"],"award-info":[{"award-number":["2041063"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.06.006","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:07:27Z","timestamp":1780718847000},"page":"1311.e1-1311.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"32","author":[{"given":"Nermen","family":"Tawfik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5574-6713","authenticated-orcid":false,"given":"Ashleigh P.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catelyn","family":"Cashion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Schwarer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5311-1293","authenticated-orcid":false,"given":"Matthew J.","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne L.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8653-4844","authenticated-orcid":false,"given":"Michael","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Coutsouvelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shevon","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-7540","authenticated-orcid":false,"given":"Louis","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Cirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushrut S.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafqat","family":"Inam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5609-3937","authenticated-orcid":false,"given":"Bradley J.","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun A.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-1766","authenticated-orcid":false,"given":"David J.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Orla","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9497-0996","authenticated-orcid":false,"given":"David J.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jtct.2026.06.006_bib0001","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","article-title":"Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease","volume":"16","author":"Cantoni","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.006_bib0002","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"issue":"20","key":"10.1016\/j.jtct.2026.06.006_bib0003","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.006_bib0004","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.bbmt.2016.07.009","article-title":"Cytomegalovirus status and the outcome of T cell\u2013replete reduced-intensity allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Verduyn Lunel","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.006_bib0005","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2017.07.025","article-title":"Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring","volume":"23","author":"Yong","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.006_bib0006","doi-asserted-by":"crossref","first-page":"169.e1","DOI":"10.1016\/j.jtct.2021.12.014","article-title":"Risk factors for early cytomegalovirus reactivation and impact of early cytomegalovirus reactivation on clinical outcomes after T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Mariotti","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.006_bib0007","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood.2025030416","article-title":"Posttransplant cyclophosphamide in HLA-matched peripheral blood transplantation: what's next?","volume":"147","author":"Curtis","year":"2026","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jtct.2026.06.006_bib0008","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.006_bib0009","doi-asserted-by":"crossref","first-page":"213.e1","DOI":"10.1016\/j.jtct.2022.01.011","article-title":"Risk of cytomegalovirus infection with post-transplantation cyclophosphamide in haploidentical and HLA-matched unrelated donor transplantation","volume":"28","author":"Jamy","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.006_bib0010","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2022009112","article-title":"Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation","volume":"7","author":"Ueda Oshima","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.006_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.01.082","article-title":"Cytomegalovirus reactivations in allogeneic hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplantation cyclophosphamide","volume":"30","author":"Chorao","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"16","key":"10.1016\/j.jtct.2026.06.006_bib0012","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2018016493","article-title":"Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation","volume":"2","author":"Chen","year":"2018","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.jtct.2026.06.006_bib0013","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jtct.2026.06.006_bib0014","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.006_bib0015","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.006_bib0016","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41409-025-02670-7","article-title":"Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide","volume":"60","author":"Schmitz","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.006_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13994","article-title":"Effective CMV prophylaxis with high-dose valaciclovir in allogeneic hematopoietic stem-cell recipients at a high risk of CMV infection","volume":"25","author":"Douglas","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.006_bib0018","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jtct.2026.06.006_bib0019","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/bloodadvances.2021004362","article-title":"Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients","volume":"5","author":"Hill","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.006_bib0020","doi-asserted-by":"crossref","first-page":"ofad169","DOI":"10.1093\/ofid\/ofad169","article-title":"CMV infection after letermovir primary prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients","volume":"10","author":"Chavaz","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.006_bib0021","doi-asserted-by":"crossref","first-page":"510.e1","DOI":"10.1016\/j.jtct.2022.05.020","article-title":"Letermovir discontinuation at day 100 After allogeneic stem cell transplant is associated with increased CMV-related mortality","volume":"28","author":"Liu","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.006_bib0022","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.006_bib0023","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.006_bib0024","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1179\/joc.2008.20.1.140","article-title":"Prevention of cytomegalovirus reactivaction after allogenic hematopoietic stem cell transplantation with valganciclovir: single center experience","volume":"20","author":"Rzepecki","year":"2008","journal-title":"J Chemother"},{"key":"10.1016\/j.jtct.2026.06.006_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/2040620721998124","article-title":"Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation","volume":"12","author":"Li","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"12","key":"10.1016\/j.jtct.2026.06.006_bib0026","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.006_bib0027","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.006_bib0028","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"393","author":"Curtis","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.006_bib0029","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.006_bib0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.006_bib0031","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V99.8.3050","article-title":"Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants","volume":"99","author":"Ljungman","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.006_bib0032","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory cmv for use in clinical trials: 2024 update from the transplant associated virus infections forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.006_bib0033","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1080\/10428194.2022.2042686","article-title":"Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide","volume":"63","author":"Freyer","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.006_bib0034","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12185-023-03635-6","article-title":"Efficacy of letermovir in HLA-haploidentical hematopoietic transplantation with posttransplant cyclophosphamide","volume":"118","author":"Nakagawa","year":"2023","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.006_bib0035","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12185-022-03348-2","article-title":"Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis","volume":"116","author":"Mori","year":"2022","journal-title":"Int J Hematol"},{"issue":"23","key":"10.1016\/j.jtct.2026.06.006_bib0036","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1182\/bloodadvances.2023010966","article-title":"Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant","volume":"7","author":"Lin","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.006_bib0037","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:57:37Z","timestamp":1791529057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726004501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666636726004501"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.006","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}